Friday, July 19, 2024
HomeHealth ConditionsCancerAre new breast cancer drugs on the horizon?

Are new breast cancer drugs on the horizon?

American researchers recently developed a new class of molecules that may improve breast cancer treatment.

Tens of millions of women suffer from breast cancer worldwide. More than 70% of breast cancers are “ER-positive,” meaning that the cancer cells grow in response to estrogen. In order to treat this type of breast cancer, doctors use endocrine therapy to break down estrogen receptors in the cancer cells.

Small molecules called selective estrogen receptor degraders (SERDs), target and damage cancer cells’ estrogen receptors. This type of therapy is often the last line of treatment for patients with resistant or metastatic breast cancer. Currently, there is only one SERD approved by the FDA and the delivery of the drug requires painful injections. So, researchers are looking for new small molecules that can block cancer cell growth and degrade estrogen receptors in breast cancers.

A team of researchers from the United States developed a new class of SERD molecules that have a great potential to stop breast cancer tumor growth. These molecules have a unique structure that was only recently discovered to hinder estrogen receptors. The research was published in ACS Medicinal Chemistry Letters.

The structure and modular design of the new molecules allowed the researchers to make different variations SERDs with relative ease. Then, they tested 15 of these molecules on breast cancer cells. Experiments proved that the estrogen receptors in the cells were damaged and the growth of breast cancer cells slowed when treated with the novel molecules.

This research greatly increases the number of options for ER-positive breast cancer treatment. In the future, researchers plan to test a few of the most promising molecules in mice to develop them into new breast cancer drugs.

Written by Cindi A. Hoover, Ph.D.

References: Wang L, Guillen VS, Sharma N et al. New class of selective estrogen receptor degraders (SERDs): Expanding the toolbox of PROTAC degrons. 2018. ACS Med Chem Lett. 9:803-808. https://www.eurekalert.org/pub_releases/2018-10/siot-anm100318.php

Cindi Hoover PhD
Cindi Hoover PhD
Cindi has a Ph.D. in Marine Science from the University of Delaware and a B.S. in Biology from the College of William and Mary. Her research focused on the genetics and molecular biology of corals. Cindi gained scientific writing experience through her many years of work in genomics and molecular biology laboratories. She is excited to contribute to Medical News Bulletin and to help others learn about cutting-edge scientific research. In her free time, Cindi enjoys hanging out with her family, swimming, hiking, and photography.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

Prevalence of long COVID rises to nearly 7% of population

US government number crunchers published a briefing article in JAMA1, June 7, 2024, presenting the results of their latest round of analysis on long...

Joke Of The Day

The Evolution of MedicineI have an earache ...2000 BC - Here, eat this root. 1000 AD - That root is heathen.  Here, say this prayer. 1850 AD...

ADVERTISE WITH US

error: Content is read-only and copy-protected.